AbbVie Inc. (ABBV) 2024 10-K Earnings Analysis
AbbVie Inc.2024 Earnings Analysis
73/100
AbbVie's FY2024 10-K captures the post-Humira transition: revenue of $56.3B grew modestly while GAAP net income of just $4.3B was suppressed by heavy amortization of prior-acquisition intangibles (Allergan primarily). Operating cash flow of $18.8B is the truer picture — 4.40x CF/NI — and the 70.0% gross margin confirms the patent-protected pricing power remains intact. The Humira biosimilar cliff (peaked at ~$21B, now declining ~30%/year) is being replaced by Skyrizi + Rinvoq (combined ~$17B FY2024, both growing 40-50%); the 10-K's detailed product list emphasizes 'address unmet needs for patients with autoimmune diseases' as the strategic anchor. Heavy debt (97.5% debt ratio, $66.8B long-term debt against $3.3B equity) is the capital-structure risk to monitor.
Filing analysis
AbbVie Inc. 2024 10-K Analysis
This page reads AbbVie Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 73/100, or grade C.
ABBV Earnings Quality
The earnings-quality module scores 76/100, with Gross Margin: 70.0%, CF/Net Income: 4.40x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
ABBV Economic Moat Analysis
The moat-strength module scores 82/100, with Immunology Portfolio: Leader, Botox Franchise (Allergan): Durable. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
ABBV Free Cash Flow vs Net Income
CF/Net Income: 4.40x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 70/100. For the diagnostic, start with cash flow vs net income.
ABBV Key Risks from the Annual Report
The risk module scores 64/100, with Humira Cliff Trajectory: Ongoing, Goodwill Impairment: Watch. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is ABBV a High Quality Earnings Stock?
Based on this 2024 filing, ABBV needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 76/100. This is a research screen, not investment advice.
Read the report first
Understand AbbVie Inc. first, then decide if it belongs on your watchlist
The ABBV score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep ABBV with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the ABBV report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross margin of 70.0% — solid for pharma despite Humira biosimilar erosion. Skyrizi and Rinvoq carry premium gross margins similar to Humira's peak; mix shift from declining Humira to growing Skyrizi/Rinvoq preserves the blended margin.
OCF of $18.8B against NI of just $4.3B = 4.40x conversion — the highest ratio in this batch. GAAP NI is suppressed by amortization of Allergan purchase accounting intangibles (~$6B/year) plus ImmunoGen + Cerevel integration charges. Cash-based earnings power is multiples of reported NI.
Combined Skyrizi + Rinvoq revenue of ~$17B grew 45%+ YoY — successfully absorbing Humira decline. Skyrizi (IL-23 psoriasis/IBD) and Rinvoq (JAK inhibitor, multiple autoimmune indications) together now exceed Humira's pre-biosimilar peak, and management believes the combined franchise will surpass Humira's $21B peak.
Humira revenue has been in accelerated decline since biosimilar launches in January 2023. FY2024 Humira revenue ~$9B vs peak ~$21B in FY2022. Trajectory continues into FY2025-26 as biosimilar adoption spreads across payer formularies.
Earnings quality scores 76/100. The headline GAAP NI of $4.3B dramatically understates underlying earnings power — the 4.40x CF/NI ratio captures this cleanly. 70.0% gross margin is maintained through the Humira cliff because Skyrizi + Rinvoq carry equivalent premium economics. The real story is the successful biosimilar-proof pivot; the accounting is just noisy because of Allergan amortization.
Moat Strength
The 10-K lists Humira as treating 'rheumatoid arthritis (moderate to severe), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, juvenile idiopathic arthritis, ulcerative colitis' — the deep indication breadth Skyrizi and Rinvoq are now replicating (and exceeding in some indications). This therapeutic-area dominance is structural.
The $63B Allergan acquisition (2020) added Botox (therapeutic + aesthetic), Juvederm, and a neuroscience portfolio (Vraylar). Botox holds ~60%+ global market share in injectable aesthetics and a dominant position in therapeutic indications. Diversification away from autoimmune is a real hedge.
Oncology (Imbruvica, Venclexta, acquired ImmunoGen's Elahere for ovarian cancer) + neuroscience (Vraylar, Ubrelvy, acquired Cerevel's emraclidine for schizophrenia) are building as the third and fourth therapeutic pillars. Not yet Humira-scale franchises but diversify the future revenue base.
Skyrizi patents run into mid-2030s; Rinvoq into early 2030s; Vraylar mid-2030s. The staggered expiration profile avoids another single-point cliff like Humira's. The 10-K emphasizes AbbVie is 'dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines' — pipeline continuity is the strategic commitment.
Moat strength scores 82/100. The immunology franchise has successfully made the Skyrizi + Rinvoq transition — a rare execution feat in pharma post-patent-cliff. Allergan adds genuine diversification (aesthetics + neuroscience). Oncology and neuroscience are the emerging third/fourth pillars. Staggered patent expirations avoid concentration risk on any single molecule. The moat is wide but not as durable as a brand-consumer moat (KO) or toll bridge (V) — pharma is fundamentally a sequence of patent cycles.
Capital Allocation
FCF of $17.8B = 31.6% FCF margin on $56.3B revenue. Cash generation is much stronger than GAAP NI suggests. This funds $6B+ annual dividend + continued debt paydown from Allergan financing.
Debt ratio of 97.5% — long-term debt of $66.8B against equity of just $3.3B. Legacy of the $63B Allergan acquisition + ImmunoGen + Cerevel. FCF comfortably services the debt, but flexibility for major new M&A is limited until more paydown.
AbbVie's dividend history traces back through the Abbott parent (52+ consecutive years of increases). Management has publicly committed to maintaining dividend growth through the Humira cliff. FY2024 dividend yield ~3.5% — unusually high for a growing pharma.
Post-Allergan, AbbVie has shifted to bolt-on deals: ImmunoGen ($10.1B, 2024) for Elahere in oncology, Cerevel ($8.7B, 2024) for emraclidine in neuroscience. Management is rebuilding the pipeline through focused acquisitions rather than another mega-deal.
Capital allocation scores 70/100. The high debt ratio is the scorecard's biggest drag — 97.5% is manageable with $17.8B FCF but limits optionality. Dividend discipline (52+ years of Abbott-heritage increases) is a structural positive and shareholder-friendly. ImmunoGen + Cerevel deals show a post-Allergan discipline: $10B bolt-ons rather than another mega-merger. Balance-sheet repair is the multi-year strategic imperative.
Key Risks
Humira revenue declining ~30%/year as biosimilars capture formulary share. Trajectory continues into FY2025-26 until revenue stabilizes at a low base. Skyrizi + Rinvoq must continue 40%+ growth to fully offset. Execution risk on the replacement pace remains.
Goodwill of $14.6B = 25.9% of assets, primarily from Allergan. If Botox or neuroscience portfolios underperform purchase-accounting assumptions, multi-billion writedowns are possible. Historically AbbVie has avoided major impairments but the GW concentration warrants monitoring.
Several AbbVie products are eligible for IRA Medicare price negotiation in future cycles. Imbruvica was in the first negotiation batch (effective 2026). Rinvoq, Skyrizi, and other franchise assets face selection in future rounds. Pricing power erodes asymmetrically.
ImmunoGen's Elahere faces competitive pressure in platinum-resistant ovarian cancer. Cerevel's emraclidine is in Phase 3 trials with readouts pending (an earlier trial disappointed in late 2024). Pipeline bets were expensive; returns on each remain unproven.
Risk profile scores 64/100 (higher = safer). Humira cliff continues to weigh on FY2025-26 but the Skyrizi + Rinvoq trajectory is reassuring. Goodwill concentration is the balance-sheet risk. IRA negotiation is a slow-motion pricing-power compression. Pipeline execution (Elahere, emraclidine) is binary and unproven. The company's cash flow + dividend discipline carry it through these risks but don't eliminate them.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.